Testosterone Replacement Therapy in CKD Stage 3a: Safety Assessment
Testosterone replacement therapy can be safely initiated in a 65-year-old man with CKD stage 3a if he has documented hypogonadism (confirmed low testosterone on two separate morning measurements), though close monitoring for specific adverse effects is essential.
Evidence-Based Safety Profile
The most recent and highest-quality evidence from a 2026 propensity-matched cohort study specifically examining TRT in CKD patients (stages 3-5) demonstrated reduced all-cause mortality (HR 0.78,95% CI 0.63-0.98) with no increased risk of cardiovascular events, prostate cancer, or dementia over 5 years of follow-up 1. This directly addresses your patient population and represents the strongest evidence available for this specific clinical scenario.
Key Safety Considerations in CKD
Cardiovascular Safety
- The 2020 American College of Physicians guideline notes that trials were not powered to assess cardiovascular events and often excluded men at increased risk 2
- However, the 2026 CKD-specific study found no excess cardiovascular risk 1
- The 2004 NEJM guideline emphasizes that no large-scale, long-term studies had established definitive cardiovascular safety at that time 3, but more recent evidence has been reassuring
CKD-Specific Risks to Monitor
Erythrocytosis is the most reproducible adverse effect:
- Occurs in approximately 17% of treated patients vs. 3.3% in controls 4
- TRT stimulates erythropoiesis, which can be problematic in CKD patients who may already have altered hematologic parameters
- Monitor hemoglobin and hematocrit closely—this is your primary safety concern
Fluid Retention and Hypertension:
- TRT may exacerbate fluid retention in CKD patients 5
- Blood pressure monitoring is essential, particularly in stage 3a CKD where cardiovascular comorbidities are common
Renal Function:
- Emerging data suggest potential renoprotective effects with preserved or improved eGFR in treated patients 6
- However, acute kidney injury signals have been noted (2.3% vs. 1.5% in controls) 4
- Monitor eGFR regularly
Clinical Benefits in CKD Population
The evidence specifically in CKD patients demonstrates meaningful improvements:
- Enhanced muscle strength and grip strength 7
- Improved quality of life scores (SF-36, AMS) 7
- Better hematologic parameters (though requiring monitoring) 7
- Reduced mortality in the CKD-specific cohort 1
Practical Implementation Algorithm
1. Confirm Hypogonadism
- Two separate fasting morning total testosterone measurements
- Document symptoms (sexual dysfunction, fatigue, muscle weakness, depression)
- CKD stage 3a alone does not justify TRT without confirmed biochemical hypogonadism
2. Exclude Contraindications
- Active prostate cancer
- Severe heart failure (NYHA Class IV)
- Untreated severe obstructive sleep apnea
- Baseline hematocrit >50%
3. Choose Formulation
- Transdermal testosterone gel is preferred over intramuscular injections 6
- Provides stable physiological levels without supraphysiological peaks
- Lower risk of excessive erythrocytosis compared to injections
4. Monitoring Protocol
First 3 months (monthly):
- Hemoglobin/hematocrit (primary safety parameter)
- Serum creatinine/eGFR
- Blood pressure
- Testosterone levels (target physiological range, not supraphysiological)
After stabilization (every 3-6 months):
- Same parameters as above
- PSA (if age-appropriate)
- Lipid panel
- Liver function tests
5. Dose Adjustment Triggers
- Hold therapy if: Hematocrit >54%, acute decline in eGFR >25%, uncontrolled hypertension
- Reduce dose if: Hematocrit 50-54%, testosterone levels supraphysiological
Critical Pitfalls to Avoid
Don't treat without confirmed hypogonadism: The 2020 ACP guideline notes that approximately 20% of men receiving TRT had testosterone levels >300 ng/dL at baseline 2—this represents inappropriate prescribing
Don't ignore erythrocytosis: This is the most consistent adverse effect and requires proactive monitoring, not reactive management
Don't use intramuscular preparations as first-line: The "roller coaster" effect of IM testosterone 3 combined with supraphysiological peaks increases erythrocytosis risk in CKD patients
Don't assume functional hypogonadism: Obesity and metabolic syndrome can cause reversible testosterone suppression 4—address these first if present
Bottom Line
For your 65-year-old male with CKD 3a and documented hypogonadism, TRT is safe with appropriate monitoring. The CKD-specific mortality benefit 1 and quality of life improvements 7 support treatment, while the absence of increased cardiovascular or oncologic risk in this population 1 provides reassurance. Use transdermal formulations and monitor hematocrit monthly during initiation—this is your primary safety concern in the CKD population.